TY  - GEN
AU  - Garg,Aakriti
AU  - Kumar,Anoop
TI  - Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication
SN  - 2212-3911
PY  - 2019///0103
KW  - Diabetes Mellitus, Type 2
KW  - drug therapy
KW  - Disease Progression
KW  - Glucagon-Like Peptides
KW  - adverse effects
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Immunoglobulin Fc Fragments
KW  - Recombinant Fusion Proteins
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Systematic Review
UR  - https://doi.org/10.2174/1574886313666180601082412
ER  -